|
Engineering Tighter Binding Spherical Nucleic Acids
Application
Method to enhance the affinity of spherical nucleic acids for their targets.
Key Benefits
Facile method for molecular printing on surface of NP.
Massive improvement of SNA’s binding affinity to the target can provide strategies in applications for therapeutics and diagnostics.
May maximize DNA density on the NP surface.
Market...
Published: 11/2/2020
Contributor(s):
|
|
Small Molecule for Treatment or Prevention of Uremic Cardiomyopathy
Application
Small molecule urea transporter (UT) inhibitors to treat or prevent conditions associated with chronic kidney disease.
Key Benefits
Provides a cardio-protective benefit in CKD patients.
Suppresses cardiac hypertrophy and fibrosis.
Market Summary
Cardiovascular complications commonly occur in patients with chronic kidney disease...
Published: 11/2/2020
Contributor(s): Jeff Sands, Janet Klein, Xiaonan Wang
|
|
Galectin-9 Directed CAR T-cells for Overcoming Resistance to Chemotherapy in Hematological Malignancies
Application
Anti-human Galectin-9-directed chimeric antigen receptor (CAR) T-cells for treatment of hematological malignancies (B-ALL, T-ALL, and DLBCL) in normal, overweight, and obese patients.
Key Benefits
Can be used as a stand-alone or in-combination product to treat patients with hematological malignancies, particularly overweight and obese...
Published: 10/13/2020
Contributor(s): Curtis Henry, Miyoung (Mi-Young) Lee, Sunil Raikar, Jamie Hamilton, Anthony Ross
|
|
Small Molecule for Treatment of Alzheimer’s Disease and Cancer
Application
New family of AEP inhibitors for neurodegenerative diseases or cancer.
Key Benefits
Non peptide, small molecule inhibitor of AEP.
Alzheimer candidate is Blood-Brain Barrier (BBB) permeable.
AEP inhibitors are a potential candidate for AD and cancer.
Market Summary
Alzheimer’s disease (AD) is the most common dementia affecting...
Published: 10/1/2020
Contributor(s): Keqiang Ye
|
|
Small Molecule for Treatment or Prevention of Uremic Cardiomyopathy
Application
Small molecule urea transporter (UT) inhibitors to treat or prevent conditions associated with chronic kidney disease.
Key Benefits
Provides a cardio-protective benefit in CKD patients.
Suppresses cardiac hypertrophy and fibrosis.
Market Summary
Cardiovascular complications commonly occur in patients with chronic kidney disease...
Published: 6/15/2020
Contributor(s): Jeff Sands, Janet Klein, Xiaonan Wang
|
|
Plant-Based Small Molecules for Treatment of MRSA Infections
Application
Small molecule inhibitor of the accessory gene regulator (agr) for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections.
Key Benefits
Targeted system is non-essential for S. aureus growth, creating less selective pressure for resistance.
Does not harm beneficial host bacteria.
May potentially be used concomitantly...
Published: 4/23/2020
Contributor(s): Cassandra Quave, Akram Salam, Gina Porras Brenes, James Lyles
|
|
Small Molecule Inhibitor of Akt Activity for Lung Cancer Treatment
Application
Mcl-1/Akt targeting small molecule with strong antitumor activity against lung cancer.
Key Benefits
Novel molecule.
Novel target presents new path to lung cancer treatment.
Potentially extend survival rate of lung cancer patients.
Market Summary
Lung cancer is the number one leading cause of death among cancer patients. Patients...
Published: 4/17/2020
Contributor(s): Xingming Deng
|
|
Reprogramming Human Urine Stem Cells into Vascular Tissue
Application
System to generate vascular progenitor cells within naturally constructed (or formed) biomatrices from urine cells.
Key Benefits
Nearly limitless supply of source cells.
Non-invasive method for harvesting source cells.
Efficient endothelial cell generation with fewer steps and faster generation time than current standard for differentiating...
Published: 1/23/2020
Contributor(s): Young-Sup Yoon, Young-Doug Sohn, Sang-Ho Lee
|
|
Small Molecule for Treatment-Resistant Lung Cancer
Application
Small molecule agonist for treating cancers involving KRAS mutations.
Key Benefits
Specifically targets mutant KRAS in non-small-cell lung carcinoma (NSCLC).
Selective for mutant KRAS lung cancer cells over normal cells.
Non-toxic to normal cells.
Market Summary
Lung cancer is the leading cause of cancer death in the US. Lung cancer...
Published: 1/14/2020
Contributor(s): Xingming Deng
|
|
Subunit-Selective NMDAR Antagonists for Treatment of Neurological Disorders
Application
GluN2C/2D selective inhibitors that modulate N-methyl-D-aspartic acid receptors (NMDAR) in a subunit-selective manner for treatment of neurological disorders.
Key Benefits
Specifically targets NMDARs that contain the GluN2C/2D subunit.
Higher potency and efficacy compared to previously reported GluN2C/2D-selective modulators.
Market...
Published: 1/10/2020
Contributor(s): Yao Jing, Stephen Traynelis, Dennis Liotta
|
Emory UniversityOffice of Technology Transfer